Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Avelumab Clinically Active in Advanced Gastric/GEJ Cancer

January 23rd 2016

The investigational anti–PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.

Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC

January 23rd 2016

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hong on High-Dose Hypofractionated Proton Beam Therapy for Liver Cancer

January 23rd 2016

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

Neoadjuvant Sorafenib Shows Significant Activity in HCC

January 23rd 2016

Nearly a quarter of patients with resectable hepatocellular carcinoma experienced major tumor necrosis of greater than or equal to 50% following preoperative treatment with sorafenib.

Nivolumab Shows Clinical Activity in Gastric Cancer

January 22nd 2016

The PD-1 inhibitor nivolumab (Opdivo) had an overall response rate of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction cancer.

Pembrolizumab Active in Advanced Esophageal Carcinoma

January 22nd 2016

The PD-1 inhibitor pembrolizumab (Keytruda) elicited encouraging activity with mild adverse events as a treatment for patients with advanced PD-L1–positive esophageal carcinoma.

Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC

January 22nd 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.

Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC

January 22nd 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Nivolumab Active in Heavily Pretreated Esophageal Cancer

January 22nd 2016

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

Liposomal Irinotecan OS Advantage Maintained in Updated Pancreatic Cancer Data

January 21st 2016

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer

January 21st 2016

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

Dr. Chak on Challenges With Screening For Esophageal Cancer

January 21st 2016

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

New Neoadjuvant Regimen Shows Similar Efficacy, Less Toxicity in Rectal Cancer

January 19th 2016

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

Everolimus Emerges as New Standard of Care for GI NETs

January 19th 2016

Everolimus reduced the risk of disease progression by at least 40% in patients with either gastrointestinal neuroendocrine tumors or NETs of unknown primary origin.

Results for Lu-Dotatate in Patients With Midgut NETs Continue to Impress

January 19th 2016

For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.

Multitargeted Drug Slows CRC as Third-Line Therapy

January 21st 2015

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Dr. Laura Dawson on HCC Challenges

January 19th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, talks about the challenges in treating hepatocellular carcinoma (HCC).

Monocyte-Targeting Agent Active in Locally Advanced Pancreatic Cancer

January 18th 2015

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

Lanreotide Effective in Pancreatic NET Subgroup

January 17th 2015

Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.

NEXT PAGE
PREVIOUS PAGE